Talecris Biotherapeutics shareholders approved the company’s proposed $4 billion takeover by of Spain this afternoon, but the deal still needs approval from U.S. antitrust regulators.
During a meeting at the Research Triangle Park Marriott, shareholders owning 85 percent of Talecris’ outstanding common stock voted in favor of the deal.
Grifols acquisition of Talecris won’t close before March 21, and Talecris CEO Larry Stern told shareholders that the deadline could be extended further.
“There can be no assurance that Grifols will reach resolution with the [Federal Trade Commission] by March 20, 2011,” Stern said.
“Certainly, however, the FTC, Grifols and we would not be engaging in discussions and extending the timeline if we did not believe that these discussions were worthwhile. We remain optimistic that Grifols will ultimately reach resolution with the FTC.”
Grifols announced in June its plan to buy Talecris, which is based in Research Triangle Park and is North Carolina’s largest biotechnology company.